See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) - free report >>
Image: Bigstock
Is Corbus Pharmaceuticals Holdings (CRBP) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corbus Pharmaceuticals Holdings (CRBP - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Corbus Pharmaceuticals Holdings is a member of the Medical sector. This group includes 833 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRBP is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CRBP's full-year earnings has moved 7.43% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, CRBP has returned 14.73% so far this year. At the same time, Medical stocks have gained an average of 10.05%. As we can see, Corbus Pharmaceuticals Holdings is performing better than its sector in the calendar year.
Breaking things down more, CRBP is a member of the Medical - Drugs industry, which includes 175 individual companies and currently sits at #73 in the Zacks Industry Rank. On average, this group has gained an average of 19.22% so far this year, meaning that CRBP is slightly underperforming its industry in terms of year-to-date returns.
CRBP will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.